OVERVIEW

Breakthroughs in Nuclear Medicine for Neurology and Oncology is organized by American Roentgen Ray Society (ARRS).

Expiration Date: June 12, 2031

Description:
With the completion of several large clinical trials in nuclear medicine leading to significant breakthroughs for both dementia and cancer patients, this Online Course highlights PET imaging of proteinopathies for neurodegenerative disease, amyloid PET for dementia, FES-PET for breast cancer, as well as updates to treatments such as PRRT and Radium-223.

Learning Outcomes and Modules
After completing this course, the learner should be able to:

  • Explain the impact of PET imaging on the diagnosis and understanding of dementia.
  • Discuss the benefits of novel imaging agents for oncology.
  • Describe the landscape of therapeutic radiopharmaceuticals.
  • Describe the role of nuclear medicine in theranostics.
Credits

Accreditation:
ARRS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

The ARRS designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • 2 AMA PRA Category 1 Credits™
  • 2 CME
  • TARGET AUDIENCE

    Physician

    SPECIALITIES

    Nuclear MedicineNeurologyOncology

    RELATED ONLINE COURSES